Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Lunai Bioworks Inc. (LNAI)

NCM · Biotechnology

$2.240.00 (0.00%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$10.2M
P/E (TTM)
EPS
$-61.52
Div Yield
52W Range
$1.21–$25.60
Beta
0.35

Company overview

Next earnings: 2026-09-28(62d)

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Peers in Biotechnology

All in industry →

Recent press releases

April 2026

3 months agoPRE 14AHealthcare

Lunai Bioworks Inc. — PRE 14A Filing

LNAILunai Bioworks Inc.

# 🧾 What This Document Is This is a **PRELIMINARY PROXY STATEMENT (PRE 14A)**. Think of it as an advance notice and information packet sent to shareholders before a major vote. Lunai Bioworks is calling a special meeting because they need shareholders to approve a critical move to stay listed on th

Read summaryView on SEC EDGAR

March 2026

4 months ago8-KHealthcare

Lunai Bioworks Inc. — 8-K Filing

LNAILunai Bioworks Inc.

# 🔖 What This Document Is This is an **8-K filing** with an attached **Exchange Agreement** (Exhibit 10.1). An 8-K is a "current report" companies use to announce major events to shareholders. 👉 In simple terms: Lunai Bioworks is announcing a deal to **swap company debt for ownership shares**. A

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Lunai Bioworks Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
497,011 sh-4.0%
166,744 sh-17.7%
127,314 sh+0.0%
131,015 sh+3.5%
37,402 sh+74.8%
24,220 sh● NEW
35,728 sh0.0%
20,632 sh● NEW

People at Lunai Bioworks Inc.

All people →

No officers or directors have been indexed for Lunai Bioworks Inc..

Quarterly financials

Full financials →
Revenue trend
12/24
NI -$7.3M
03/25
NI $189.2K
09/25
NI $2.8M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.13
Prior: $0.00
Revenue sparkline
Lunai Bioworks Inc. (LNAI) Stock Quote, Press... | Cayman Journal | Cayman Journal